hotspot -WSS

hotspot

author：leisure time 2025-09-30 16:26:48 - browse：595

Nathan Guo, left, and his wife Ada Lio encourage their 17-month-old son, Lucas Guo, to take steps in his gate trainer at their home in Somerville, MA on February 16, 2024. Lucas has one of the world's rarest diseases, ZTTK Syndrome — Lucas Guo, a boy with a rare neurological condition called ZTTK, is encouraged by his father, Nathan Guo, and mother, Ada Lio, to take some steps. Craig F. Walker/The Boston Globe

SOMERVILLE — At 19 months old, Lucas Guo has never crawled, walked, or stood by himself. He babbles but can’t say words. He struggles to chew and swallow. He gets most of his nutrition through a feeding tube attached to his belly.

Lucas has one of the world’s rarest diseases, ZTTK syndrome, a complex neurological disorder caused by a genetic mutation. Scientists have documented only about 60 cases worldwide and estimate that, at most, it afflicts several hundred people — far too few to encourage drug makers to find a treatment.

That economic reality has driven Lucas’s parents, Ada Lio and Nathan Guo, to take things into their own hands. Working through a small foundation, they are trying to raise $10 million to develop a treatment or cure for ZTTK in five years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Regeneron agrees to White House price limits on anti

WSS

White House touts steps to stem shortages of cancer treatments

Generate Biomedicines machine learning biotech raises $273M

How many hemophilia patients actually want gene therapy?

Telehealth for opioid use disorder is lifesaving

Walmart eyes Medicare Advantage provider ChenMed

Amid AI frenzy, a top HHS official's quest to create safeguards

leisure time

hotspot

hotspot

Medicare details structure of new drug price negotiation program

PEPFAR is under serious threat — and so is global health

Walensky prepares to leave CDC — and Congress — behind

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Bright Health sells Medicare Advantage business to Molina

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

United colonoscopy coverage change 'may cost lives,' doctors say

WATCH: Why do bright lights make us see spots?

How one medical school became remarkably diverse

Popular nasal decongestant doesn't actually relieve congestion

leisure time

FDA proposes changes to key medical devices approval pathway

First U.S. drug developed to treat liver disease MASH is approved

IRA could hurt research into orphan drugs for rare diseases

How medical schools plan to diversify without affirmative action

Why scientists need input from humanists on sensitive research

How to save health care price transparency rules

hotspot

focus

hotspot

leisure time